SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GMED - GenoMed Inc.
GMED 71.82+1.1%2:14 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen5/5/2005 2:25:49 PM
  Read Replies (1) of 347
 
GenoMed CEO Invited to Speak at Harvard Medical School 25th Class Symposium

Contact: David Moskowitz MD GenoMed, Inc. dwmoskowitz@genomed.com tel. 314-983-9933


ST. LOUIS--(May 5, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that its CEO, David Moskowitz MD, has been invited to speak on Clinical Genomics at the 25th Class Symposium at Harvard Medical School on June 9, 2005 (http://134.174.17.106/alumni/program-05.pdf

Said Dr. Moskowitz, "It's a tremendous honor to be selected to speak at our 25th medical class reunion. Since publishing three years ago that angiotensin I-converting enzyme ('ACE') might be the aging gene, I've been trying hard to get the word out. Last week at 'World DNA and Genome Day' in Dalian, China, the reception was quite enthusiastic. Speaking at Harvard next month should be equally productive. I've already gotten inquiries from Harvard Medical School alumni who've seen the Class Day program. The point of my talk will be that all physicians should be practicing clinical genomics already."

Added Dr. Moskowitz, "GenoMed's primary goal right now is to educate the 80 million American Baby Boomers and their physicians, not to mention the rest of the world, that medicine has already been revolutionized. Unfortunately, an entire cohort of kidney patients is just now going on dialysis in the U.S. because their physicians didn't hear about our published results three years ago. If we'd gotten to these patients then, we could have kept them off the kidney machine now. Getting the word out to patients and their physicians in time is absolutely critical. Disease doesn't wait."

About GenoMed

GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. Disease Management (DM) is the only business in healthcare which profits by lowering healthcare costs. GenoMed uses clinical genomics to keep patients healthier and out of the hospital. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that GenoMed applied for patents based on its finding that the ACE gene is associated with many common diseases.


.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext